PD-1抑制剂在晚期胃癌治疗的研究进展
Progress of PD-1 inhibitor in the treatment of advanced gastric cancer
许威 1阎龙 1杨佳兴 1许淑梅 1吴金玲 1范瑞芳1
作者信息
- 1. 730050 兰州市,中国人民解放军联勤保障部队第九四〇医院普通外科
- 折叠
摘要
中国是胃癌的高发国家,多数患者确诊时已逐步发展局部进展期或晚期,而晚期胃癌作为我国胃癌治疗领域所无法避免的一大难题,始终缺乏有效的治疗手段.随着程序性死亡受体 1(PD-1)或程序性死亡受体配体 1(PD-L1)单克隆抗体的问世,研究发现其能有效提高晚期胃癌患者的总生存率,因而在世界范围胃癌治疗领域掀起了免疫研究热潮.本文就PD-1抑制剂的作用机制、临床免疫疗效、不良反应等方面的进展进行综述.
Abstract
China is a high-incidence country of gastric cancer(GC),most patients have been diagnosed when the development of local progression or advanced stage,and advanced GC as our country's treatment field can not avoid a major problem,there is always a lack of effective treatment.With the advent of programmed death receptor 1(PD-1)or programmed death receptor ligand 1(PD-L1)monoclonal antibody,that it can effectively improve the overall survival rate of patients with advanced GC have been found.Therefore,there is a great upsurge of immunologic research for GC worldwide.This article reviews the progress of PD-1 inhibitors in the mechanism of action,clinical immunotherapeutic efficacy,adverse reactions and so on.
关键词
胃癌/免疫治疗/PD-1抑制剂Key words
gastric cancer/immunotherapy/programmed death receptor 1(PD-1)inhibitor引用本文复制引用
基金项目
甘肃省青年科技项目(22JR11RA002)
甘肃省自然科学基金(21JR1RA186)
军队后勤科研计划(20BJZ23)
出版年
2024
NETL
NSTL
万方数据